Sartorius Stedim: reduces targets for 2023
(CercleFinance.com) - On announcing its preliminary results, Sartorius Stedim Biotech has reduced its guidance for 2023, now expecting sales to fall by around 19% (and around 14% excluding Covid-19-related items) at constant exchange rates.
The pharmaceutical industry supplier says that its underlying EBITDA margin should now be just over 28% this year, compared with 35% in the previous year, against a former expectation of around 30%.
According to its preliminary figures, it recorded sales of around E2.07bn in the first nine months of 2023, down by almost 19% at constant exchange rates, while its underlying EBITDA margin fell by six points to 29%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The pharmaceutical industry supplier says that its underlying EBITDA margin should now be just over 28% this year, compared with 35% in the previous year, against a former expectation of around 30%.
According to its preliminary figures, it recorded sales of around E2.07bn in the first nine months of 2023, down by almost 19% at constant exchange rates, while its underlying EBITDA margin fell by six points to 29%.
Copyright (c) 2023 CercleFinance.com. All rights reserved.